Shanghai Nianxing Industrial Co., Ltd
China
Product Name: SB203580
Price:
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang

DC Chemicals Limited
China
Product Name: SB-203580
Price: $300.0/100mg $600.0/250mg $1200.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

ShangHai DC Chemicals Co.,Ltd
China
Product Name: SB-203580
Price: ￥Inquiry/1g
Purity: 98.9%
Stocking Period: 1 Day
Contact: Tony Lai

Henan Tianfu Chemical Co., Ltd.
China
Product Name: 4-(4-FLUOROPHENYL)-2-(4-METHYLSULFINYLPHENYL)-5-(4-PYRIDYL) 1H-IMIDAZOLE
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson

152121-47-6

152121-47-6 structure

Name: SB203580
Chemical Name: 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine
CAS Number: 152121-47-6
Molecular Formula: C₂₁H₁₆FN₃OS
Molecular Weight: 377.435
Catalog: Biochemical Inhibitor Mitogen-activated protein kinase (MAPK) P38 MAPK inhibitor
Create Date: 2018-12-26 21:22:49
Modify Date: 2024-01-02 18:31:02
SB 203580 is a widely used p38 MAPK inhibitor with an IC50 of 0.3-0.5 μM. It shows more than 100-fold selectivity over PKB, LCK, and GSK-3β.

Name	4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine
Synonyms	PB 203580 4-(4-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine RWJ 64809 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(pyridin-4-yl)imidazole 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole MFCD00922198 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole 4-{4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-1H-imidazol-5-yl}pyridine 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(pyridin-4-yl)-1H-imidazole Pyridine, 4-[4-(4-fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-1H-imidazol-5-yl]- Pyridine,4-(5-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-4-yl) SB 203580 SB203580 SB-203580

Description	SB 203580 is a widely used p38 MAPK inhibitor with an IC50 of 0.3-0.5 μM. It shows more than 100-fold selectivity over PKB, LCK, and GSK-3β.
Related Catalog	Signaling Pathways >> PI3K/Akt/mTOR >> Akt Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Autophagy >> Mitophagy Signaling Pathways >> MAPK/ERK Pathway >> p38 MAPK Research Areas >> Inflammation/Immunology
Target	p38 MAP kinase:0.3-0.5 μM (IC50, in IL-2-stimulated T cells) PKB:3-5 μM (IC50, in IL-2-stimulated T cells) Autophagy Mitophagy
In Vitro	SB 203580 inhibits IL-2-driven T cell proliferation with an IC50 of 3-5 μM, SB 203580 is able to inhibit the activity of PDK1 in a dose-dependent manner with an IC50 in the 3-10 μM range[1]. SB 203580 at a concentration of 1 μM is sufficient for inhibiting p38 kinase activity in TF-1 cells. SB 203580 at 5 and 10 μM enhances NF-κB-mediated gene transcription independently of phosphorylation on the transactivation domains of the p65 subunit. SB 203580 at 10 μM enhances phosphorylation of ERK1/2 and JNK[1].
In Vivo	All animals challenged with NS (noninfected controls) and treated with either SB203580 or placebo survive. Compared with placebo, pretreatment with the highest dose of SB203580 (100 mg/kg) 1 hour before E. coli increases the hazards ratio of death. With E. coli, compared with placebo, at 48 hours, but not 24 hours, low and high dose SB203580 decrease phosphorylated p38 MAPK and the ratio of phosphorylated to total p38. High dose SB203580 decreases lung neutrophils on histology at 24 hours in a trend approaching significance (p = 0.09) and increases them significantly at 48 hours (p = 0.01) in patterns different over time[3]. SB 203580 is evaluated in several models of cytokine inhibition and inflammatory disease. It is demonstrated clearly to be a potent inhibitor of inflammatory cytokine production in both mice and rats with IC50 values of 15 to 25 mg/kg[4].
Cell Assay	Phosphorylation of p38, JNK1/2, and ERK1/2 is analysed by Western blotting. Briefly, TF-1 cells are cultured for 16 h in RPMI 1640 containing 0.1% FBS and subsequently stimulated for various periods of time with medium or OA (30 ng/mL) or SB 203580(1 μM, 5 μM, 10 μM) plus OA. After harvesting, total cell extracts are prepared by resuspending the cells in 500 μL 1× sample buffer (containing 2% SDS, 10% glycerol, 2% β-mercaptoethanol, 60 mM Tris-HCl (pH 6.8) and bromophenol blue) and lysing the cells by passing them through a 23G1 needle (three times). Cell extracts are directly boiled for 10 min and stored at -20°C. Before loading, samples are again boiled for 5 min and cell extracts are resolved by running 1/10th volume on a SDS/12.5%PAGE gel (acryla-mide:bisacrylamide is 173:1) and transferred to cellulosenitrate membrane. Immunoblotting with the antibodies is performed by standard procedures and detection is performed[2].
Animal Admin	Mice[3] In survival studies, C57BL/6J mice weighing 20 g to 30 g are briefly anesthetized with isoflurane and challenged with 0.05 mL of IT normal saline (NS, noninfected controls) or E. coli (15 × 109 CFU/kg). One hour before NS challenge, mice (n = 24) receive either intraperitoneal SB203580 (100 mg/kg in 0.25 mL) or diluent only (placebo). Infected animals receive SB203580 in doses of 100, 10, 1, or 0.1 mg/kg or placebo 1 hour before IT E. coli (n = 241); SB203580 100 or 0.1 mg/kg or placebo 1 hour after E. coli (n = 121); or SB203580 100 mg/kg or placebo 12 hours after E. coli (n = 72). All animals receive ceftriaxone (100 mg/kg in 0.1 mL,subcutaneously) for 4 days and NS (0.5 mL, subcutaneously) for 1 day beginning 4 hoursafter challenge. Animals were observed every 2 hours for the initial 48 hours, every 4 hours from 48 hours to 72 hours, every 8 hours from 72 hours to 96 hours, and then twice daily until study completion (168 hours)[3].
References	[1]. Lali FV, et al. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem. 2000 Mar 10;275(10):7395-402. [2]. Birkenkamp KU, et al. The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol. 2000 Sep;131(1):99-107. [3]. Su J, et al. SB203580, a p38 inhibitor, improved cardiac function but worsened lung injury and survival during Escherichia coli pneumonia in mice. J Trauma. 2010 Jun;68(6):1317-27. [4]. Badger AM, et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 1996 Dec;279(3):1453-61. [5]. Lin Y, et al. Critical role of astrocytic interleukin-17?A in post-stroke survival and neuronal differentiation of neural precursor cells in adult mice. Cell Death Dis. 2016 Jun 23;7(6):e2273.

Density	1.4±0.1 g/cm3
Boiling Point	615.6±55.0 °C at 760 mmHg
Melting Point	249 - 250ºC
Molecular Formula	C₂₁H₁₆FN₃OS
Molecular Weight	377.435
Flash Point	326.1±31.5 °C
Exact Mass	377.099823
PSA	77.85000
LogP	4.10
Vapour Pressure	0.0±1.7 mmHg at 25°C
Index of Refraction	1.715
Storage condition	−20°C
Stability	-200C
Water Solubility	DMSO: 50 mg/mL

Symbol	GHS05, GHS07
Signal Word	Danger
Hazard Statements	H302-H318
Precautionary Statements	P280-P305 + P351 + P338
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes	Xn: Harmful;
Risk Phrases	R22;R41
Safety Phrases	26-39
RIDADR	NONH for all modes of transport
WGK Germany	3
HS Code	2818200000